Sex | Female: 26 (18.4%) |
Male: 112 (79.4%) | |
Age [years] | Mean: 64 |
Median: 66 | |
St.dev: 11 | |
Range: 30–87 | |
Portal Vein Thrombosis | No: 64 (46.4%) |
Yes: 74 (53.6%) | |
Tumour location | Right lobe: 57 (41.3%) |
Left lobe: 10 (7.2%) | |
Bilateral: 71 (51.4%) | |
Stage T | T1: 8 (5.8%) |
T2: 10 (7.2%) | |
T3: 120 (86.9%) | |
Stage N | N0: 114 (82.6%) |
N1: 24 (17.4%) | |
Stage M | M0: 116 (84.1%) |
M1: 22 (15.9%) | |
AJCC Stage | I: 7 (5.1%) |
II: 9 (6.5%) | |
III: 83 (60.1%) | |
IV: 39 (28.3%) | |
Okuda Stage | I: 31 (22.4%) |
II: 109 (77.6%) | |
BCLC Stage | A: 9 (6.5%) |
B: 29 (21.0%) | |
C: 100 (72.5%) | |
Child-Pugh Stage | A: 96 (69.6%) |
B: 42 (30.4%) | |
Hepatitis (B/C) | No: 19 (13.8%) |
Yes: 119 (86.2%) | |
Initial Alpha-feto protein (ng/mL) | Mean: 11481 |
Range: 2.4, >58300 | |
Dose prescription | 54Gy: 16 (11.6%) |
60Gy: 114 (82.6%) | |
66Gy: 8 (5.8%) |